Jon Stonehouse, BioCryst president and CEO
BioCryst officially gets partial clinical hold on lead candidate after halting enrollment
About a month after BioCryst halted three studies for its oral Factor D inhibitor BCX9930, the FDA has imposed a partial clinical hold.
The new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
